Abbott Laboratories company is prospected by companies that are selling Production, Robotics, Manufacturing, Medical technology, Shipping, SAAS, Logistics and other services. These are a few quick insights about Abbott Laboratories company that you might find valuable in your outreach.
ABBOTT COMPLETES ACQUISITION OF BIGFOOT BIOMEDICAL
(source: https://abbott.mediaroom.com/2023-09-22-Abbott-Completes-Acquisition-of-Bigfoot-Biomedical)
Intel type: Mergers & Acquisition
Date: 22 Sep 2023
Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.
The transaction expands Abbott’s presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology and furthering the company’s efforts to develop connected solutions for making diabetes management even more personal and precise.
Pursuant to the terms of the merger agreement, upon completion of the acquisition, Bigfoot became a wholly owned subsidiary of Abbott. Financial terms were not disclosed.
This insight is useful for your prospecting if your business deals with: Hiring, Healthcare, Manufacturing, Laser Marking, Account management, Transportation, Logistics and Security
Is Abbott Laboratories company a target account for you? Get insights about Abbott Laboratories company and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact
Intel type: Deals & Partnerships
Date: 21 Sep 2023
mAbxience will manufacture the biosimilars at its GMP approved facilities in Spain and Argentina. In addition, mAbxience will be responsible for achieving the clinical milestones for some of the molecules still undergoing development.
The collaboration broadens Abbott’s medicines offering in emerging countries and expands an existing agreement with mAbxience, initiated in Latin America 2018.
“The expanded collaboration with mAbxience will complement our existing branded generic medicines portfolio with state-of-the-art biosimilars,” said Daniel Salvadori, executive vice president and group president, established pharmaceuticals and nutritional products, Abbott. “With our large footprint in emerging countries and our commitment to put access and affordability at the center of what we do, this strategic collaboration will help more people in more places have access to affordable biosimilar medicines.”
This insight is useful for your prospecting if your business deals with: Data analytics, Finance, Insurance, Operations, Laser marking, Logistics, Robotics, Automation, Transportation services
Is Abbott Laboratories company a target account for you? Get insights about Abbott Laboratories company and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
Abbott breaks ground on FreeStyle Libre manufacturing plant in Ireland
(source: https://www.massdevice.com/abbott-breaks-ground-freestyle-libre-manufacturing-ireland/)
Intel type: Media, News & PR
Date: 14 April 2023
Abbott (NYSE: ABT)+
today broke ground on a new FreeStyle Libre manufacturing facility in Kilkenny, Ireland.
Jared Watkin, SVP for Abbott’s diabetes care business, shared the news of the groundbreaking in a LinkedIn post.
In August 2022, the Irish government announced that Abbott planned to spend €440 million ($450 million) to expand its operations in Ireland. The investment included the creation of a new manufacturing facility in Kilkenny. It also featured further investment in the company’s Donegal Diabetes Care site, adding 1,000 new jobs between the sites.
This insight is useful for your prospecting if your business deals with: Healthcare, Manufacturing, Account management, Laser marking, Transportation, Logistics and Security
Is Abbott Laboratories company a target account for you? Get insights about Abbott Laboratories company and 9 more accounts relevant to YOUR business, from B2Brain – set up your 14 day Free Trial from here.
